A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

被引:5
|
作者
Wu, KM
D'Amico, M
Wang, CG
Albanese, C
Pestell, RG
Mani, S
机构
[1] Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA
[4] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
关键词
HeLa cells; IAP; survivin; caspases; UCN-01; flavopiridol;
D O I
10.1007/s10637-005-1438-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least 4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.
引用
收藏
页码:299 / 309
页数:11
相关论文
共 50 条
  • [11] Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Jimeno, Antonio
    Rudek, Michelle A.
    Purcell, Thomas
    Laheru, Daniel A.
    Messersmith, Wells A.
    Dancey, Janet
    Carducci, Michael A.
    Baker, Sharyn D.
    Hidalgo, Manuel
    Donehower, Ross C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 423 - 433
  • [12] Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells
    Mack, PC
    Jones, AA
    Gustafsson, MH
    Gandara, DR
    Gumerlock, PH
    Goldberg, Z
    RADIATION RESEARCH, 2004, 162 (06) : 623 - 634
  • [13] RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
    Mack, PC
    Gandara, DR
    Bowen, C
    Edelman, MJ
    Paglieroni, T
    Schnier, JB
    Gelmann, EP
    Gumerlock, PH
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2596 - 2604
  • [14] A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
    Tianhong Li
    Scott D. Christensen
    Paul H. Frankel
    Kim A. Margolin
    Sanjiv S. Agarwala
    Thehang Luu
    Philip C. Mack
    Primo N. Lara
    David R. Gandara
    Investigational New Drugs, 2012, 30 : 741 - 748
  • [15] A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Fracasso, Paula M.
    Williams, Kerry J.
    Chen, Ronald C.
    Picus, Joel
    Ma, Cynthia X.
    Ellis, Matthew J.
    Tan, Benjamin R.
    Pluard, Timothy J.
    Adkins, Douglas R.
    Naughton, Michael J.
    Rader, Janet S.
    Arquette, Matthew A.
    Fleshman, James W.
    Creekmore, Allison N.
    Goodner, Sherry A.
    Wright, Lisa P.
    Guo, Zhanfang
    Ryan, Christine E.
    Tao, Yu
    Soares, Eliane M.
    Cai, Shi-rong
    Lin, Li
    Dancey, Janet
    Rudek, Michelle A.
    McLeod, Howard L.
    Piwnica-Worms, Helen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1225 - 1237
  • [16] A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
    Li, Tianhong
    Christensen, Scott D.
    Frankel, Paul H.
    Margolin, Kim A.
    Agarwala, Sanjiv S.
    Luu, Thehang
    Mack, Philip C.
    Lara, Primo N., Jr.
    Gandara, David R.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 741 - 748
  • [17] Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Philip C. Mack
    David R. Gandara
    Alvin H. Lau
    Primo N. Lara
    Martin J. Edelman
    Paul H. Gumerlock
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 337 - 348
  • [18] Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Mack, PC
    Gandara, DR
    Lau, AH
    Lara, PN
    Edelman, MJ
    Gumerlock, PH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (04) : 337 - 348
  • [19] A pharmacokinetic and pharmacodynamic Phase 1 study of UCN-01 and irinotecan in resistant solid tumors.
    Fracasso, PM
    Rudek, MA
    Ellis, MJ
    Goodner, SA
    Dancey, J
    McLeod, HL
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8985S - 8985S
  • [20] A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Paula M. Fracasso
    Kerry J. Williams
    Ronald C. Chen
    Joel Picus
    Cynthia X. Ma
    Matthew J. Ellis
    Benjamin R. Tan
    Timothy J. Pluard
    Douglas R. Adkins
    Michael J. Naughton
    Janet S. Rader
    Matthew A. Arquette
    James W. Fleshman
    Allison N. Creekmore
    Sherry A. Goodner
    Lisa P. Wright
    Zhanfang Guo
    Christine E. Ryan
    Yu Tao
    Eliane M. Soares
    Shi-rong Cai
    Li Lin
    Janet Dancey
    Michelle A. Rudek
    Howard L. McLeod
    Helen Piwnica-Worms
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1225 - 1237